

FRIDAY 11TH SEPTEMBER 2020
OPENING SESSION

CET (Paris, Amsterdam, Berlin) 13:00–15:15 hours

EST (New York, Montreal, Lima) 7:00 AM – 9:15 AM

CST (Beijing, Manilla, Perth) 19:00–21:15 hours

Opening	<i>Andrea Doria (Italy)</i> <i>Ronald van Vollenhoven (Netherlands)</i>
Keynote	
<i>Moderator: Andrea Doria (Italy)</i>	
Understanding and treating SLE: A new era is dawning <i>Live Q&A (15 Mins)</i>	<i>Ronald van Vollenhoven (Netherlands)</i>
Debate: New Developments in Basic Science and Clinical Research: Defining SLE	
<i>Moderator: Ricard Cervera (Spain)</i>	
The matter of the debate	<i>Ricard Cervera (Spain)</i>
A <u>majority</u> of lupus patients (will) need a biologic!	<i>David Isenberg (UK)</i>
A <u>minority</u> of lupus patients (will) need a biologic!	<i>Murray Urowitz (Canada)</i>
<i>Live Voting, Q&A and Discussion (20 Mins)</i>	<i>All</i>

PLENARY I: NEW ASPECTS IN THE MANAGEMENT OF SLE

CET (Paris, Amsterdam, Berlin) 15:30–17:00 hours

EST (New York, Montreal, Lima) 9:30 AM – 11:00 AM

CST (Beijing, Manilla, Perth) 21:30–23:00 hours

<i>Moderators: Zahir Amoura (France), Bernardo Pons-Estel (Argentina)</i>	
Measuring SLE disease activity in 2020: Perspectives from clinical research <i>Live Q&A (10 Mins)</i>	<i>Luis Ines (Portugal)</i>
Lifestyle for lupus patients: exercise, diet, and well-being: Perspectives from clinical practice <i>Live Q&A (10 Mins)</i>	<i>Chiara Tani (Italy)</i>
Microangiopathy in SLE: A diagnostic and therapeutic challenge <i>Live Q&A (10 Mins)</i>	<i>Ricard Cervera (Spain)</i>
<i>Live Panel Discussion and Q&A</i>	<i>All</i>

PLENARY II: NOVEL THERAPEUTIC DEVELOPMENTS IN 2020

CET (Paris, Amsterdam, Berlin) 17:30–19:30 hours

EST (New York, Montreal, Lima) 11:30 AM – 1:30 PM

CST (Beijing, Manilla, Perth) 23:30–01:30 hours

<i>Moderators: Richard Furie (USA), Ronald van Vollenhoven (Netherlands)</i>	
Plasma-cell directed therapies <i>Live Q&A (10 Mins)</i>	<i>Reinhard Voll (Germany)</i>
IL-12/23 directed therapies <i>Live Q&A (10 Mins)</i>	<i>Bevra Hahn (USA)</i>
Novel intracellular pathways <i>Live Q&A (10 Mins)</i>	<i>Thomas Dörner (Germany)</i>
Molecules in early development stage <i>Live Q&A (10 Mins)</i>	<i>Richard Furie (USA)</i>
<i>Live Panel Discussion and Q&A</i>	<i>All</i>

PLENARY II: NOVEL THERAPEUTIC DEVELOPMENTS IN 2020**(Recorded Session from Friday. Live Panel Discussion and Q&A)**

CET (Paris, Amsterdam, Berlin) 07:30–09:30 hours

EST (New York, Montreal, Lima) 1:30 AM–3:30 AM

CST (Beijing, Manilla, Perth) 13:00–15:30 hours

<i>Moderators: Richard Furie (USA), Ronald van Vollenhoven (Netherlands)</i>	
Plasma-cell directed therapies Recorded Q&A (10 Mins)	Reinhard Voll (Germany)
IL-12/23 directed therapies Recorded Q&A (10 Mins)	Bevra Hahn (USA)
Novel intracellular pathways Recorded Q&A (10 Mins)	Thomas Dörner (Germany)
Molecules in early development stage Recorded Q&A (10 Mins)	Richard Furie (USA)
Live Panel Discussion and Q&A	All

FOUR HOT TOPICS (SESSION 1)

CET (Paris, Amsterdam, Berlin) 10:00–11:50 hours

EST (New York, Montreal, Lima) 4.00 AM–5.50 AM

CST (Beijing, Manilla, Perth) 16:00–17:50 hours

<i>Moderator: Thomas Dörner (Germany)</i>	
Remission and low disease activity: the new targets for treatment Live Q&A (10 Mins)	George Bertias (Greece)
Belimumab helps lupus patients to achieve lupus targets Live Q&A (10 Mins)	Andrea Doria (Italy)
Can we withdraw low-dose prednisone in remitted patients? Live Q&A (10 Mins)	Zahir Amoura (France)
Can we withdraw immunosuppressants in remitted patients? Live Q&A (10 Mins)	Margherita Zen (Italy)
Live Panel Discussion and Q&A	All

CASE STUDY INTERACTIVE WORKSHOPS (SESSION 1)

CET (Paris, Amsterdam, Berlin) 12:00–13:30 hours

EST (New York, Montreal, Lima) 6:00 AM – 7:30 AM

CST (Beijing, Manilla, Perth) 18:00–19:30 hours

<i>Moderator/Facilitator: Andrea Doria (Italy)</i>	
Management of refractory skin lupus	Annegret Kuhn (Germany), Marzia Caproni (Italy)
<i>Moderator/Facilitator: Bernardo Pons-Estel (Argentina)</i>	
Management of cardiovascular risk in SLE	Murray Urowitz (Canada), Eloisa Bonfá (Brazil)
<i>Moderator/Facilitator: Sandra Navarra (Philippines)</i>	
Fertility and pregnancy issues in patients with lupus nephritis	Angela Tincani (Italy), Liz Lightstone (UK)
<i>Moderator/Facilitator: David Isenberg (UK)</i>	
Rare disease manifestations in SLE	Zahir Amoura (France), Richard Furie (USA)

PRIME TIME SESSION

CET (Paris, Amsterdam, Berlin) 13:30–15:00 hours

EST (New York, Montreal, Lima) 7:30 AM – 9:00 AM

CST (Beijing, Manilla, Perth) 19.30– 21:00 hours

Hot Topic	
<i>Moderators: Murray Urowitz (Canada), David Isenberg (UK)</i>	
Optimal assessment and monitoring of SLE patients in clinical practice <i>Live Q&A (10 Mins)</i>	<i>Alexandre Voskuyl (Netherlands)</i>
State-of-the-art	
<i>Moderators: Bevra Hahn (USA), Sandra Navarra (Philippines)</i>	
Diagnosis and treatment of neuropsychiatric lupus <i>Live Q&A (10 Mins)</i>	<i>Marcello Govoni (Italy)</i>
Covid-19 and SLE – What do we know today? <i>Live Q&A (10 Mins)</i>	<i>Fabrizio Conti (Italy)</i>

CASE STUDY INTERACTIVE WORKSHOPS (SESSION 2)

CET (Paris, Amsterdam, Berlin) 15:30–17:00 hours

EST (New York, Montreal, Lima) 9:30 AM – 11:00 AM

CST (Beijing, Manilla, Perth) 21:30–23:00 hours

<i>Moderator/Facilitator: Andrea Doria (Italy)</i>	
Management of refractory skin lupus	<i>Annegret Kuhn (Germany), Marzia Caproni (Italy)</i>
<i>Moderator/Facilitator: Bernardo Pons-Estel (Argentina)</i>	
Management of cardiovascular risk in SLE	<i>Murray Urowitz (Canada), Eloisa Bonfá (Brazil)</i>
<i>Moderator/Facilitator: Sandra Navarra (Philippines)</i>	
Fertility and pregnancy issues in patients with lupus nephritis	<i>Angela Tincani (Italy), Liz Lightstone (UK)</i>
<i>Moderator/Facilitator: David Isenberg (UK)</i>	
Rare disease manifestations in SLE	<i>Zahir Amoura (France), Richard Furie (USA)</i>

FOUR HOT TOPICS (SESSION 2)

CET (Paris, Amsterdam, Berlin) 17:30–19:40 hours

EST (New York, Montreal, Lima) 11:30 AM – 1:40 PM

CST (Beijing, Manilla, Perth) 23:30–01:40 hours

<i>Moderator: Thomas Dörner (Germany)</i>	
Remission and low disease activity: the new targets for treatment <i>Live Q&A (10 Mins)</i>	<i>George Bertisias (Greece)</i>
Belimumab helps lupus patients to achieve lupus targets <i>Live Q&A (10 Mins)</i>	<i>Andrea Doria (Italy)</i>
Can we withdraw low-dose prednisone in remitted patients? <i>Live Q&A (10 Mins)</i>	<i>Zahir Amoura (France)</i>
Can we withdraw immunosuppressants in remitted patients? <i>Live Q&A (10 Mins)</i>	<i>Margherita Zen (Italy)</i>
<i>Live Panel Discussion and Q&A</i>	<i>All</i>

More information available at www.lupus-academy.org.

PRE-RECORDED SESSION*: CASE STUDY WORKSHOPS (SESSION 3)

CET (Paris, Amsterdam, Berlin) 07:30 – 11:45 hours

EST (New York, Montreal, Lima) 1:30 AM – 5:45 AM

CST (Beijing, Manilla, Perth) 13:30–17:45 hours

<i>Moderator/Facilitator: Andrea Doria (Italy)</i>	
Management of refractory skin lupus	<i>Annegret Kuhn (Germany), Marzia Caproni (Italy)</i>
<i>Moderator/Facilitator: Bernardo Pons-Estel (Argentina)</i>	
Management of cardiovascular risk in SLE	<i>Murray Urowitz (Canada), Eloisa Bonfá (Brazil)</i>
<i>Moderator/Facilitator: Sandra Navarra (Philippines)</i>	
Fertility and pregnancy issues in patients with lupus nephritis	<i>Angela Tincani (Italy), Liz Lightstone (UK)</i>
<i>Moderator/Facilitator: David Isenberg (UK)</i>	
Rare disease manifestations in SLE	<i>Zahir Amoura (France), Richard Furie (USA)</i>

*Please note that this session (presentation and discussion) is pre-recorded and there will not be an opportunity to participate in discussion.

PRE-RECORDED SESSION*

Keynote	
<i>Moderator: Andrea Doria (Italy)</i>	
Understanding and treating SLE: A new era is dawning <i>Recorded Q&A (15 Mins)</i>	<i>Ronald van Vollenhoven (Netherlands)</i>
Debate: New Developments in Basic Science and Clinical Research: Defining SLE	
<i>Moderator: Ricard Cervera (Spain)</i>	
The matter of the debate	<i>Ricard Cervera (Spain)</i>
A <u>majority</u> of lupus patients (will) need a biologic!	<i>David Isenberg (UK)</i>
A <u>minority</u> of lupus patients (will) need a biologic!	<i>Murray Urowitz (Canada)</i>
<i>Recorded Voting, Q&A and Discussion (20 Mins)</i>	
Hot Topic	
<i>Moderators: Murray Urowitz (Canada), David Isenberg (UK)</i>	
Optimal assessment and monitoring of SLE patients in clinical practice <i>Recorded Q&A (10 Mins)</i>	<i>Alexandre Voskuyl (Netherlands)</i>

*Please note that this session (presentation and discussion) is pre-recorded and there will not be an opportunity to participate in discussion.

MEET THE EDITOR

CET (Paris, Amsterdam, Berlin) 11:05 – 12:45 hours

EST (New York, Montreal, Lima) 5:50 AM – 6:45 AM

CST (Beijing, Manilla, Perth) 17:50–18:45 hours

<i>Moderator: Ronald van Vollenhoven (Netherlands)</i>	
Introduction: What is happening in the world of publishing?	<i>Ronald van Vollenhoven (Netherlands)</i>
Workshop: How do I get my manuscript published—in the best possible journal?	
Tips for reviewers: make it work for the authors and yourself	

ROUNDTABLE: REFRACTORY LUPUS MANIFESTATIONS: DEFINITION AND TREATMENT

CET (Paris, Amsterdam, Berlin) 13:00 – 15:00 hours

EST (New York, Montreal, Lima) 7:00 AM – 9:00 AM

CST (Beijing, Manilla, Perth) 19:00–21:00 hours

<i>Moderators: Andrea Doria (Italy), Ronald van Vollenhoven (Netherlands)</i>	
Refractory lupus nephritis <i>Live Q&A (10 Mins)</i>	<i>Sandra Navarra (Philippines)</i>
Refractory lupus cytopenias <i>Live Q&A 10 Mins)</i>	<i>Eloisa Bonfá (Brazil)</i>
Refractory musculoskeletal manifestations <i>Live Q&A (10 Mins)</i>	<i>Bernardo Pons-Estel (Argentina)</i>
Refractory and/or catastrophic APS in SLE <i>Live Q&A (10 Mins)</i>	<i>Ricard Cervera (Spain)</i>
<i>Panel Discussion and Q&A</i>	<i>All</i>
Close	<i>Andrea Doria (Italy) Ronald van Vollenhoven (Netherlands)</i>